What it sells
Population health analytics powered by wastewater.
Business model breakdown
Buyer: who owns the budget?
UnverifiedPublic health agency leaders (federal biodefense, state/local health departments) and pharma commercial/clinical development teams.
Trigger: what makes them buy now?
Need earlier outbreak and substance-use signals than clinical reports (e.g. measles, H5N1, fentanyl); pharma needing faster trial recruitment and campaign timing.
Workflow: what inputs become what output?
Biobot provides sampling kits, logistics, lab analysis and data dashboards; wastewater is tested for 50+ pathogens and substances, and predictive data feeds into outbreak response, trial recruitment, marketing/DSP targeting.
Economics: what it saves and how it charges
Data/analytics subscriptions to government and pharma; pharma claims a two-week commercial head start; funded in part by SBIR Phase I-III awards.
Distribution: how it reaches customers
Demo-led sales (Book a Demo) segmented by government, pharma and treatment plants; partnerships with CDC's National Wastewater Surveillance System.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2018 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.